AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved… read more.
Pfizer Inc will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30… read more.
Amgen announced that the global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or… read more.
Incyte announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago…. read more.
Bayer and Vividion Therapeutics, Inc. will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place… read more.
Radiation from imaging could lead to lung, breast and other future cancers, with 10-fold increased risk for babies CT scans may account for 5% of all cancers annually,… read more.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has… read more.
A groundbreaking study has revealed a significant link between the frequency of chest x-ray referrals from GPs and earlier diagnosis and improved survival rates for lung cancer patients. … read more.
Exelixis, Inc. announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30… read more.
Eli Lilly and Company announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR)… read more.
AbbVie announced the final analysis of the confirmatory Phase III MIRASOL trial evaluating the efficacy and safety of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
